Merck & Co, known as MSD outside the United States and Canada, has won patent infringement suits against Mylan Pharmaceuticals Inc., in respect of Zetia and Vytorin. The US District Court for the District of New Jersey has ruled in Merck’s favour in two jointly related patent infringement suits. “The court appropriately ruled that the patent for Zetia and Vytorin in the US is valid and enforceable,” said Bruce N. Kuhlik, executive vice president and general counsel of Merck. The patent at issue in this trial is RE 42,461 which covers ezetimibe, an active ingredient in both Zetia and Vytorin and expires April 2017.
